Technologies

Immunoplex Vaccine Technology

Memcine Pharma Inc. is developing a novel, Universal Vaccine technology, Immunoplexing, for the development of an intranasal influenza vaccine available to the general population, and to elderly, infants, immunocompromised, and other groups previously ineligible for the current intranasal flu vaccine.
This Flu Vaccine will protect against seasonal strains of influenza by engaging and activating both arms of the immune system. This technology will enable the rapid distribution of flu vaccine to large populations.
Immunoplexing enhances the immune response to vaccine components by targeting them for immune recognition by the body’s natural defenses. This is in contrast to conventional vaccine enhancers, which function by inducing general inflammation. Immunoplexe’s targeting of immune components limits the side-effects associated with conventional enhancers.
While important for developing this intranasal Flu Vaccine, the Immunoplex technology is a platform technology invented to enable the rapid development of more efficacious, safer vaccines.

Chemical composition:

The Immunplexing Technology consists of a defined antibody recognition element (ARE) readily recognized by a mass produced monoclonal Ab. The epitope tag is the linear immunodominant peptide from polio virus VP-1 protein. This peptide has been used for decades as a portion of the polio vaccine. The Ab that recognizes the ARE is being developed through genetic means. Importantly, because of the composition of Immunoplex vaccines, they can be administered by multiple routes (intranasal, subcutaneous, epicutaneous, etc…), and each route tested for optimal immune response.